<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01077505</url>
  </required_header>
  <id_info>
    <org_study_id>107032</org_study_id>
    <nct_id>NCT01077505</nct_id>
  </id_info>
  <brief_title>An Evaluation of the Pharmacokinetics of an Oral Contraceptive (Brevicon) When Co-administered With Albiglutide .</brief_title>
  <official_title>An Open-label Study to Evaluate the Pharmacokinetics of an Oral Contraceptive Containing Norethindrone and Ethinyl Estradiol When Co-administered With GSK716155 in Healthy Adult Female Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will be an open-label study to evaluate the effect of albiglutide on the&#xD;
      pharmacokinetics and pharmacodynamics of a standard oral contraceptive regimen (Brevicon).&#xD;
      The primary objective of this study is to demonstrate the lack of effect of albiglutide doses&#xD;
      on the pharmacokinetics of norethindrone and ethinyl estradiol in healthy female subjects.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will be an open-label study in at least one center to evaluate the effect of&#xD;
      albiglutide administration on the pharmacokinetics and pharmacodynamics of a standard oral&#xD;
      contraceptive regimen (Brevicon). The primary objective of this study is to demonstrate the&#xD;
      lack of effect of albiglutide doses on the pharmacokinetics of norethindrone and ethinyl&#xD;
      estradiol in healthy female subjects.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 15, 2010</start_date>
  <completion_date type="Actual">November 24, 2010</completion_date>
  <primary_completion_date type="Actual">November 24, 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AUC0-24 of norethindrone and ethinyl estradiol after OC alone in Period 1 and after OC with albiglutide in Period 2.</measure>
    <time_frame>Day 21</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cmax, Cmin, tmax, and t½ of norethindrone and ethinyl estradiol after OC alone on Day 21 of Period 1 and after OC with albiglutide on Day 21 of Period 2.</measure>
    <time_frame>Day 21 of each period.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Predose serum levels of LH and FSH after OC alone and after OC with albiglutide.</measure>
    <time_frame>Days 1 and 11 through 14 of each period.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Predose serum levels of progesterone after OC alone and after OC with albiglutide.</measure>
    <time_frame>Day 21 of each period.</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>albiglutide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>albiglutide 50mg weekly</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>albiglutide</intervention_name>
    <description>albiglutide 50mg weekly subcutaneous injection</description>
    <arm_group_label>albiglutide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oral contraceptive (Brevicon)</intervention_name>
    <description>Oral contraceptive (Brevicon)</description>
    <arm_group_label>albiglutide</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy female subjects, defined as individuals who are free from clinically&#xD;
             significant illness or disease as determined by their medical history, physical&#xD;
             examination, clinical laboratory tests, and 12-lead ECG;&#xD;
&#xD;
          -  Women of childbearing potential must use protocol-defined contraceptive methods;&#xD;
&#xD;
          -  BMI is 19 to 30 kg/m2 and body weight ≥50 kg (110 lbs) and &lt;114 kg (&lt;250 lbs);&#xD;
&#xD;
          -  Aspartate aminotransferase (AST), ALT, alkaline phosphatase, and bilirubin is &lt;/=1.5 ×&#xD;
             ULN;&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any clinically relevant abnormality identified on the screening medical assessment,&#xD;
             laboratory examination, or ECG;&#xD;
&#xD;
          -  Blood pressure ≥140/90 mm Hg or heart rate &gt;100 beats/minute at Screening;&#xD;
&#xD;
          -  Corrected QT (QTc) intervals &gt;450 msec (per ECG machine interpretation);&#xD;
&#xD;
          -  Pregnant or nursing females;&#xD;
&#xD;
          -  A positive prestudy hepatitis B surface antigen, positive hepatitis C antibody, or HIV&#xD;
             result within 3 months of Screening;&#xD;
&#xD;
          -  Current or chronic history of liver disease, or known hepatic or biliary abnormalities&#xD;
             (with the exception of Gilbert's syndrome or asymptomatic gallstones);&#xD;
&#xD;
          -  Smoking or using any nicotine products, including smoking cessation patches containing&#xD;
             any amount of nicotine within the 6 months before Screening;&#xD;
&#xD;
          -  Women of childbearing potential who are unwilling or unable to use an appropriate&#xD;
             method of contraception;&#xD;
&#xD;
          -  Subjects have participated in a clinical trial and have received an investigational&#xD;
             product within the following time period prior to the first dosing day in the current&#xD;
             study: 30 days, 5 half-lives, or twice the duration of the biological effect of the&#xD;
             investigational product (whichever is longer);&#xD;
&#xD;
          -  History of substance abuse within the past year as determined by the investigator;&#xD;
&#xD;
          -  History of alcohol abuse defined as an average weekly intake of &gt;7 drinks;&#xD;
&#xD;
          -  Positive urine drug screen at Screening or predose during the Run-in Period and on Day&#xD;
             1 of Periods 1 and 2;&#xD;
&#xD;
          -  Use of prescription or nonprescription drugs, vitamins, dietary/herbal supplements&#xD;
             including St. John's Wort, nonsteroidal antiinflammatory medications, and aspirin&#xD;
             within 14 days or 5 half-lives, whichever is longer prior to the first dose of&#xD;
             investigational product;&#xD;
&#xD;
          -  Willing to refrain from consuming grapefruit or cranberry products (such as juice,&#xD;
             fruit, or nutritional supplements) at any time during participation in the study;&#xD;
&#xD;
          -  Donation of blood in excess of 500 mL within 56 days prior to dosing or intention of&#xD;
             donating in the month after completing the study;&#xD;
&#xD;
          -  History of thyroid dysfunction or an abnormal (i.e., outside normal reference range)&#xD;
             thyroid function test assessed by thyroid stimulating hormone (TSH) at Screening;&#xD;
&#xD;
          -  History of drug allergy or other allergy, which, in the opinion of the responsible&#xD;
             study physician, contradicts the subject's participation;&#xD;
&#xD;
          -  History of any condition that would contraindicate OC administration (including&#xD;
             hypertension, stroke, ischemic heart disease, venous thromboembolism, carcinoma of the&#xD;
             breast, etc.);&#xD;
&#xD;
          -  History of type 1 or 2 diabetes mellitus;&#xD;
&#xD;
          -  History of migraine if aged &gt;35 years or has focal symptoms associated with migraine;&#xD;
&#xD;
          -  Any condition that would affect drug transit time or absorption (e.g.,&#xD;
             gastrointestinal bypass surgery, partial or total gastrectomy, small bowel resection,&#xD;
             chronic diarrhea, vagotomy, chronic gastroesophageal reflux disease, malabsorption,&#xD;
             colostomy, Crohn's disease, ulcerative colitis, or celiac sprue); or&#xD;
&#xD;
          -  Previous or current receipt of exenatide or any other GLP 1 agonist;&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78744</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.clinicalstudydatarequest.com</url>
    <description>Researchers can use this site to request access to anonymised patient level data and/or supporting documents from clinical studies to conduct further research.</description>
  </link>
  <reference>
    <citation>Bush M, Scott R, Watanalumlerd P, Zhi H, Lewis E. Effects of multiple doses of albiglutide on the pharmacokinetics, pharmacodynamics, and safety of digoxin, warfarin, or a low-dose oral contraceptive. Postgrad Med. 2012 Nov;124(6):55-72. doi: 10.3810/pgm.2012.11.2613.</citation>
    <PMID>23322139</PMID>
  </reference>
  <verification_date>June 2017</verification_date>
  <study_first_submitted>February 25, 2010</study_first_submitted>
  <study_first_submitted_qc>February 25, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 1, 2010</study_first_posted>
  <last_update_submitted>June 13, 2017</last_update_submitted>
  <last_update_submitted_qc>June 13, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 14, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>pharmacokinetics</keyword>
  <keyword>GSK716155</keyword>
  <keyword>Brevicon</keyword>
  <keyword>albiglutide</keyword>
  <keyword>healthy female volunteers</keyword>
  <keyword>oral contraceptive</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Contraceptive Agents</mesh_term>
    <mesh_term>Norethindrone acetate, ethinyl estradiol, ferrous fumarate drug combination</mesh_term>
    <mesh_term>Contraceptives, Oral</mesh_term>
    <mesh_term>rGLP-1 protein</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.</ipd_description>
  </patient_data>
  <study_docs>
    <study_doc>
      <doc_id>107032</doc_id>
      <doc_type>Individual Participant Data Set</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>107032</doc_id>
      <doc_type>Informed Consent Form</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>107032</doc_id>
      <doc_type>Study Protocol</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>107032</doc_id>
      <doc_type>Annotated Case Report Form</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>107032</doc_id>
      <doc_type>Clinical Study Report</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>107032</doc_id>
      <doc_type>Statistical Analysis Plan</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>107032</doc_id>
      <doc_type>Dataset Specification</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
  </study_docs>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

